Ovid Therapeutics Inc. (OVID)

3.1500 -0.0500 (-1.56%) At close: 04:00PM EDT

Ovid Therapeutics Inc.

41 Ninth Avenue
14th Floor
New York, NY 10001
United States
646 661 7661
https://www.ovidrx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 40

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir	President, CEO & Chairman	923.54k	N/A	1953
Mr. Jeffrey A. Rona	Principal Financial Officer, Principal Accounting Officer & Chief Business and Financial Officer	686.28k	N/A	1968
Mr. Jason Tardio M.B.A.	Chief Operating Officer	652.84k	N/A	1978
Ms. Lora Pike	Senior Director of Investor Relations & Public Relations	N/A	N/A	N/A
Mr. Thomas Michael Perone J.D., M.B.A.	General Counsel	632.11k	N/A	1966
Mr. Simon D. Kelner	Chief Human Resources Officer	N/A	N/A	1974
Dr. Dirk Haasner	Senior Vice President of Global Manufacturing & CMC QA	416.95k	N/A	1965
Dr. Todd F. Baumgartner M.D., M.P.H.	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Dr. Julia Tsai Ph.D.	Senior Vice President of Clinical Development	N/A	N/A	1975
Ms. Meg Alexander	Chief Strategy Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Corporate governance

Ovid Therapeutics Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.